iBio Inc

iBio Inc. is a biotechnology company headquartered in San Diego, California. The company employs 70 individuals and generates approximately $2 million in annual revenue. iBio focuses on developing safer and more effective immunotherapies for challenging cancers. Their core technology, the Discovery Platform, utilizes artificial intelligence to guide drug discovery, aiming to make therapeutic development smarter, more precise, and faster. This platform allows them to pursue difficult-to-drug targets with greater potential and less competition. iBio's pipeline currently includes nine immuno-oncology candidates, targeting various cancers, including solid tumors, glioblastoma, and head and neck cancers. Their approach addresses the limitations of traditional antibody discovery methods, which often rely heavily on chance and can be time-consuming and costly. For more information, please visit iBio Inc.'s website at ibioinc.com.